X
Xavier Bessa
Researcher at Autonomous University of Barcelona
Publications - 133
Citations - 6391
Xavier Bessa is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Colorectal cancer & Population. The author has an hindex of 38, co-authored 126 publications receiving 5815 citations. Previous affiliations of Xavier Bessa include University of Barcelona & Pompeu Fabra University.
Papers
More filters
Journal ArticleDOI
Colonoscopy versus Fecal Immunochemical Testing in Colorectal-Cancer Screening
Enrique Quintero,Antoni Castells,Luis Bujanda,Joaquín Cubiella,Dolores Salas,Angel Lanas,Montserrat Andreu,Fernando Carballo,Juan Diego Morillas,Cristina Hernández,Rodrigo Jover,Isabel Montalvo,Juan Arenas,Eva Laredo,Vicent Hernandez,Felipe Iglesias,Estela Cid,Raquel Zubizarreta,Teresa Sala,Marta Ponce,Mercedes Andrés,Gloria Teruel,Antonio Peris,María-Pilar Roncales,Mónica Polo-Tomás,Xavier Bessa,Olga Ferrer-Armengou,Jaume Grau,Anna Serradesanferm,Akiko Ono,José Cruzado,Francisco Pérez-Riquelme,Inmaculada Alonso-Abreu,Mariola de la Vega-Prieto,Juana María Reyes-Melián,Guillermo Cacho,José Díaz-Tasende,Alberto Herreros-de-Tejada,Carmen Poves,Cecilio Santander,Andrés González-Navarro +40 more
TL;DR: Subjects in the FIT group were more likely to participate in screening than were those in the colonoscopy group, and more adenomas were identified in thecolorectal cancer group.
Journal ArticleDOI
Accuracy of Revised Bethesda Guidelines, Microsatellite Instability, and Immunohistochemistry for the Identification of Patients With Hereditary Nonpolyposis Colorectal Cancer
Virginia Piñol,Antoni Castells,Montserrat Andreu,Sergi Castellví-Bel,Cristina Alenda,Xavier Llor,Rosa M. Xicola,Francisco Rodríguez-Moranta,Artemio Payá,Rodrigo Jover,Xavier Bessa +10 more
TL;DR: The revised Bethesda guidelines constitute a useful approach to identify patients at risk for HNPCC in patients fulfilling these criteria, and both microsatellite instability testing and immunostaining are equivalent and highly effective strategies to further select those patients who should be tested for MSH2/MLH1 germline mutations.
Journal ArticleDOI
Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis
Andrés Cárdenas,Pere Ginès,Juan Uriz,Xavier Bessa,Joan Manuel Salmerón,Antoni Mas,Rolando Ortega,B. Calahorra,D. De Las Heras,Jaime Bosch,Vicente Arroyo,Juan Rodés +11 more
TL;DR: Renal failure is a common event in patients with cirrhosis and gastrointestinal bleeding, the occurrence of which is mainly related to the severity of bleeding and baseline liver function.
Journal ArticleDOI
Postoperative Surveillance in Patients With Colorectal Cancer Who Have Undergone Curative Resection: A Prospective, Multicenter, Randomized, Controlled Trial
Francisco Rodríguez-Moranta,Joan Saló,A. Arcusa,Jaume Boadas,Virginia Piñol,Xavier Bessa,Eduard Batiste-Alentorn,Antonio M. Lacy,Salvadora Delgado,Joan Maurel,Josep M. Piqué,Antoni Castells +11 more
TL;DR: A more intensive surveillance strategy improves the prognosis of patients with stage II colorectal cancer or those with rectal tumors and inclusion of regular performance of colonoscopy seems justified up to the fifth year of follow-up.
Journal ArticleDOI
Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer
Rodrigo Jover,Pedro Zapater,Antoni Castells,Xavier Llor,Montserrat Andreu,Joaquín Cubiella,Virginia Piñol,Rosa M. Xicola,Luis Bujanda,Josep Maria Reñe,Juan Clofent,Xavier Bessa,Juan Diego Morillas,David Nicolás-Pérez,Artemio Payá,Cristina Alenda +15 more
TL;DR: Benefit from 5-FU adjuvant chemotherapy depends on the MMR status of tumours in patients with colorectal cancer but this benefit from chemotherapy cannot be extended to patients with MMR deficient tumours.